Loading…
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-87M | $-90M | $-78M | -34.1% | -100.0% | - |
| 2024 | $1M | $-72M | $-75M | $-71M | -24.2% | - | - |
| 2023 | $0M | $-33M | $-36M | $-52M | -19.5% | - | - |
| 2022 | $0M | $-52M | $-55M | $-55M | 37.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0.93 | 0 |
| Operating Expense | 56.52 | 55.58 | 83.53 | 103.33 |
| Operating Income | -56.52 | -55.58 | -82.61 | -103.33 |
| EBITDA | -51.99 | -33.01 | -71.89 | -87.25 |
| EBIT | -55.19 | -36.30 | -75.13 | -90.35 |
| Pretax Income | -55.19 | -36.32 | -75.14 | -90.35 |
| Net Income | -55.19 | -36.32 | -75.14 | -90.35 |
| Net Income Common Stockholders | -55.19 | -36.32 | -75.14 | -90.35 |
| Total Expenses | 56.52 | 55.58 | 83.53 | 103.33 |
| Interest Expense | 0 | 0.01 | 0.01 | 0.01 |
| Interest Income | 1.34 | 2.95 | 8.47 | 11.55 |
| Research And Development | 47.51 | 44.39 | 60.92 | 75.01 |
| Selling General And Administration | 9.01 | 11.19 | 22.61 | 28.32 |
| Normalized EBITDA | -51.99 | -49.36 | -71.89 | -87.25 |
| Normalized Income | -55.19 | -52.67 | -75.14 | -90.35 |
| Basic EPS | -37.80 | -73.83 | -4.28 | 0 |
| Diluted EPS | -37.80 | -73.83 | -4.28 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 16.36 | 0.57 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 16.36 | 0.57 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -55.19 | -36.32 | -75.14 | -90.35 |
| Reconciled Depreciation | 3.20 | 3.30 | 3.25 | 3.09 |
| Net Interest Income | 1.33 | 2.94 | 8.46 | 11.54 |
| Net Income From Continuing And Discontinued Operation | -55.19 | -36.32 | -75.14 | -90.35 |
| Total Operating Income As Reported | -56.52 | -55.58 | -82.61 | -103.33 |
| Diluted Average Shares | 1.46 | 4.66 | 17.57 | 0 |
| Basic Average Shares | 1.46 | 0.49 | 17.57 | 0 |
| Diluted NI Availto Com Stockholders | -55.19 | -36.32 | -75.14 | -90.35 |
| Net Income Including Noncontrolling Interests | -55.19 | -36.32 | -75.14 | -90.35 |
| Net Income Continuous Operations | -55.19 | -36.32 | -75.14 | -90.35 |
| Other Income Expense | -0.01 | 16.33 | -0.99 | 1.44 |
| Other Non Operating Income Expenses | -0.01 | -0.03 | -0.99 | 1.44 |
| Special Income Charges | 0 | 16.36 | 0.57 | 0 |
| Restructuring And Mergern Acquisition | 0 | -16.36 | -0.57 | 0 |
| Net Non Operating Interest Income Expense | 1.33 | 2.94 | 8.46 | 11.54 |
| Interest Expense Non Operating | 0 | 0.01 | 0.01 | 0.01 |
| Interest Income Non Operating | 1.34 | 2.95 | 8.47 | 11.55 |
| General And Administrative Expense | 9.01 | 11.19 | 22.61 | 28.32 |
| Other Gand A | 9.01 | 11.19 | 10.70 | 11.35 |
| Salaries And Wages | 0 | 0 | 11.91 | 16.97 |
| Operating Revenue | 0 | 0 | 0.93 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Neurogene Inc.this co. | NGNE | $414M | - | 1.55 | -34.1% | -1.53 |
| Fulgent Genetics, Inc. | FLGT | $427M | - | 0.41 | -5.5% | -1.98 |
| Vanda Pharmaceuticals Inc. | VNDA | $424M | - | 1.27 | -67.4% | -1.16 |
| Strata Critical Medical, Inc. | SRTA | $424M | - | 1.52 | 14.8% | -64.52 |
| Lexeo Therapeutics, Inc. | LXEO | $421M | - |
| 1.68 |
| -40.5% |
| -2.27 |
| Benitec Biopharma Inc. | BNTC | $416M | - | 2.22 | -39.0% | -4.75 |
| Emergent BioSolutions Inc. | EBS | $413M | 8.59 | 0.80 | 10.1% | 3.79 |
| Community Health Systems, Inc. | CYH | $404M | 0.83 | -0.27 | -60.8% | 7.88 |
| Enanta Pharmaceuticals, Inc. | ENTA | $402M | - | 3.18 | -126.5% | -6.01 |
| Peer Median | - | 4.71 | 1.40 | -39.7% | -2.13 | |